Please assess the completion status of the following clinical trial:

Trial Title: Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with symptoms suggestive for ACS presenting within 48 hours after onset in the ER/ Chest Pain Unit (CPU)~* Patient has at least one elevated high-sensitivity troponin I or T value~* Chest pain is classified as non-ACS, despite elevated hsTn (e.g. because of missing troponin dynamics)~* At least 50 years of age~Exclusion Criteria:~* Indication for antiplatelet therapy (e.g transient ischemic attack, or stable coronary artery diseases -CAD) or anticoagulation therapy (such as atrial fibrillation)~* Indication for anti-lipid therapy~* Any evidence of an acute myocardial necrosis (e.g imaging evidence of new regional wall motion abnormality, or significant ST-segment-T wave (ST-T) changes in ECG)~* Untreated clinically significant CAD requiring revascularization~* Hemoglobin value below 8 mg/d, and/or creatinine kinase ≥3 times ULN, and/or AST or ALT ≥3 times ULN~* Active malignancy of any organ system, treated or untreated. Subjects have to be in remission for at least 36 months to be eligible.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: ACTIVE_COMPARATOR): Aspirin 100 mg once daily and Placebo Atorvastatin once daily
- Atorvastatin (Type: ACTIVE_COMPARATOR): Atorvastatin 20 mg once daily and Placebo Aspirin once daily
- Aspirin-Atorvastatin (Type: EXPERIMENTAL): Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Aspirin once daily and Placebo Atorvastatin once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).